UY32142A - Preparación de una quinoliniloxidifenilciclopropanodicarboxamida - Google Patents

Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Info

Publication number
UY32142A
UY32142A UY0001032142A UY32142A UY32142A UY 32142 A UY32142 A UY 32142A UY 0001032142 A UY0001032142 A UY 0001032142A UY 32142 A UY32142 A UY 32142A UY 32142 A UY32142 A UY 32142A
Authority
UY
Uruguay
Prior art keywords
preparation
quinoliniloxidifenilciclopropanodicarboxamida
compound
relates
present
Prior art date
Application number
UY0001032142A
Other languages
English (en)
Inventor
Zhou Xiaoming
Nicole Marie Deschamps
Michael Tolar Martin
Michael John Monteith
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of UY32142A publication Critical patent/UY32142A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar un compuesto de la fórmula III siguiente: en el que R1-R4 son como se define en la presente memoria. La presente invención también se refiere a la preparación de compuestos intermedios usados para preparar el compuesto de fórmula III:
UY0001032142A 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida UY32142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10045208P 2008-09-26 2008-09-26

Publications (1)

Publication Number Publication Date
UY32142A true UY32142A (es) 2010-05-31

Family

ID=42058136

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032142A UY32142A (es) 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Country Status (8)

Country Link
US (1) US8314232B2 (es)
EP (1) EP2339918A4 (es)
JP (1) JP5587324B2 (es)
CN (1) CN102227164A (es)
AR (1) AR075084A1 (es)
TW (1) TW201035017A (es)
UY (1) UY32142A (es)
WO (1) WO2010036831A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 N-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
WO2010111063A1 (en) 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG185073A1 (en) * 2010-04-29 2012-12-28 Deciphera Pharmaceuticals Llc Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites
SG10201609324UA (en) 2010-07-16 2017-01-27 Exelixis Inc C-met modulator pharmaceutical compositions
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
GEP20247677B (en) 2011-02-10 2024-10-10 Exelixis Inc Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス, インク. 癌および骨癌疼痛の治療方法
AU2012312364B2 (en) 2011-09-22 2017-11-09 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) * 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN102977014B (zh) * 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103044263A (zh) * 2013-01-14 2013-04-17 中国药科大学 一种治疗囊性纤维化药物的中间体的制备方法
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 N­(4­〔[6,7­비스(메틸옥시)퀴놀린­4­일]옥시〕페닐)­n′­(4­플루오로페닐)시클로프로판­1,1­디카복사미드의 대사물
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
CN110117254B (zh) * 2019-06-20 2022-05-13 江苏君若药业有限公司 卡博替尼的制备方法
CN112194622A (zh) * 2020-09-24 2021-01-08 上海毕得医药科技有限公司 一种5-氯喹啉-4-醇的合成方法
WO2024110606A1 (en) 2022-11-25 2024-05-30 Synthon B.V. A process for preparation of cabozantinib or tivozanib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer

Also Published As

Publication number Publication date
US20100081805A1 (en) 2010-04-01
AR075084A1 (es) 2011-03-09
EP2339918A4 (en) 2012-06-06
CN102227164A (zh) 2011-10-26
TW201035017A (en) 2010-10-01
EP2339918A1 (en) 2011-07-06
JP2012503671A (ja) 2012-02-09
JP5587324B2 (ja) 2014-09-10
WO2010036831A1 (en) 2010-04-01
US8314232B2 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
IN2012DN02751A (es)
CU20110052A7 (es) Compuestos orgánicos
MX377930B (es) Proceso para fabricar compuestos de quinolona.
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
MX2019003738A (es) Compuestos antivirales.
ECSP10010434A (es) Inhibidores de hsp90
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CR20110286A (es) Proceso para la preparacion de derivados de l-alanina protegidos
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
CR20120592A (es) Intermedios de agomelatina y métodos de preparación de estos
CR20110208A (es) Proceso para la preparación de benzonorbornenos
CY1119697T1 (el) Μεθοδος παρασκευης ενωσεων α-γαλακτοζυλο κεραμιδιων
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
BR112012008952A2 (pt) microbicidas
MX2013002656A (es) Nuevo proceso.

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20101124